Saba Capital Income & Opportunities Fund II (NYSE:SABA – Get Free Report) major shareholder Saba Capital Management, L.P. sold 4,453 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $8.46, for a total transaction of $37,672.38. Following the completion of the transaction, the insider now owns 3,450,271 shares of the company’s stock, valued at $29,189,292.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Saba Capital Income & Opportunities Fund II Trading Down 0.5 %
Shares of SABA traded down $0.04 during midday trading on Tuesday, hitting $8.39. The stock had a trading volume of 98,407 shares, compared to its average volume of 117,340. Saba Capital Income & Opportunities Fund II has a fifty-two week low of $7.28 and a fifty-two week high of $8.65.
Saba Capital Income & Opportunities Fund II Announces Dividend
The business also recently declared a monthly dividend, which will be paid on Monday, September 30th. Investors of record on Tuesday, September 10th will be issued a dividend of $0.058 per share. This represents a $0.70 annualized dividend and a dividend yield of 8.30%. The ex-dividend date of this dividend is Tuesday, September 10th.
Institutional Trading of Saba Capital Income & Opportunities Fund II
Saba Capital Income & Opportunities Fund II Company Profile
Saba Capital Income & Opportunities Fund II is a closed-ended fixed income mutual fund launched and managed by Saba Capital Management, L.P. The fund invests in fixed income markets across the globe. It primarily invests in government bonds. The fund is actively managed. It benchmarks the performance of its portfolio against the J.P.
Featured Stories
- Five stocks we like better than Saba Capital Income & Opportunities Fund II
- 3 Warren Buffett Stocks to Buy Now
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Why Are Stock Sectors Important to Successful Investing?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is a Special Dividend?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Saba Capital Income & Opportunities Fund II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Saba Capital Income & Opportunities Fund II and related companies with MarketBeat.com's FREE daily email newsletter.